CLDX Celldex Therapeutics, Inc.

When biopharmaceutical companies advance platform technologies targeting complex immunological pathways, market participants must weigh clinical efficacy against the heavy capital requirements of drug development. Celldex Therapeutics (NASDAQ:CLDX) embodies the classic profile of a clinical-stage innovator: a proprietary mast cell inhibitor platform, a robust balance sheet insulated by substantial cash reserves, and multi-indication optionality across severe […]

Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.

H.C. Wainwright called the Phase 3 results a “compelling” late-stage assessment of Barzolvolimab in a patient population with a significant unmet need.

Celldex Therapeutics (NASDAQ:CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the pr

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.

Celldex Therapeutics (NASDAQ:CLDX) shares gained 8% on Tuesday after the company reported positive topline results from two Phase 3 trials evaluating barzolvolimab in patients with chronic spontaneous urticaria (CSU). Both EMBARQ-CSU1 and EMBARQ-CSU2 met their primary endpoints and all key secondary endpoints, demonstrating statistically significant improvements in disease activity compared with placebo.

Celldex Therapeutics' (CLDX) two Phase 3 trials of barzolvolimab in patients with chronic spontaneou

Celldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock’s recent strength in sharper focus for investors. See our latest analysis for Celldex Therapeutics. Celldex Therapeutics shares have climbed strongly over the past year, with a year to date share price return of 54.42% and a 1 year total shareholder return of 101.89%. The recent 90 day share price gain of 29.21% suggests momentum has been...

Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operations increased to US$0.94. Over the first half of 2026, revenue slipped to just US$0.037 million as the company’s net loss rose to US$152.19 million, highlighting the cost intensity of its operations relative to minimal reported revenue. We will examine how this widening net loss and sharply...

Celldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises questions about how much of its pipeline story is already reflected in the current price. The share price has returned 101.9% over the past year, which sets a high bar for any further upside to be justified by future execution. Progress in Celldex Therapeutics' allergy and immunology programs, including ongoing late stage studies and early...

Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 studies for barzolvolimab following its latest development review. Celldex discontinued its Phase 2 trial in prurigo nodularis after the program did not show sufficient efficacy. For readers who want to see more stock ideas linked to similar healthcare themes, the next step is to explore 43...

Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.

Celldex Therapeutics (NASDAQ:CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies. Anthony M

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.

Celldex announced that its experimental drug barzolvolimab missed key goals in a mid-stage study for prurigo nodularis.

Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.